3 July 2026

Day 3 post-oral-presentation filing deadline. Filings locked but not yet visible on FDA docket (3–7 business day posting lag expected July 7–10). Zero PCAC vacancy appointments in 36+ weeks. ACIP FACA ruling continues dampening committee restructuring across all federal advisory panels. 3-member panel structurally locked. 20 days to July 23 meeting. New detail: BPC-157 is being reviewed specifically for ulcerative colitis indication — a narrow therapeutic framing that gives PCAC a specific clinical use case to evaluate rather than the broad "compounding for longevity" umbrella. If advocacy groups submitted strong GI data (European clinical literature exists), this could marginally favor Cat 1. But no new safety data has emerged and no USP monograph exists. Holding at coin-flip.

Same vacancy dynamics and 3-member panel structure. Binary-outcome concern persists: small panels historically favor all-pass or all-defer over nuanced 2-of-4 splits. The ulcerative colitis framing for BPC-157 could make it the "strongest candidate" of the four — if BPC-157 gets Cat 1 based on GI evidence quality and one other peptide (KPV, with its anti-inflammatory data) follows, the forecast resolves true. TB-500 and MOTS-C have weaker clinical profiles. Public comment docket closes July 22. Filing quality remains the shared catalyst. Holding.

(fewer than 1M enrollees by Dec 31). Day 3 post-launch. Program operationally smooth across Medicare Part D plans, MA-PD, SNPs, and EGWP. No enrollment data yet — first figures expected mid-July. KFF denominator: ~3.8M met eligibility criteria in 2023. 1M = 26% penetration in 6 months — historically fast for any Medicare demonstration. The "no-opt-in" architecture is genuinely novel: prescribers submit PA through the Humana/LI NET central processor, and coverage activates automatically at $50 copay. AARP flagged "a lot of places for things to fall through the cracks" but no problems have surfaced. MFN deal ($245/mo manufacturer price) removes manufacturer resistance as a friction factor. Next reassessment: first enrollment data mid-July.

Month 19 post-facility acquisition, within 18–24-month M&A-to-launch base rate. Key language from Feb 2026 earnings call: "developing a peptide-based product line as part of a longevity specialty planned to launch this year." This is the most definitive public commitment yet — "planned to launch this year" is stronger than prior "exploring" or "developing" language. HIMS stock surged 50% in one week following RFK peptide push (Forbes). OneTwenty 10+ weeks live with zero FDA enforcement continues creating competitive pressure. No launch announcement yet. Next catalysts: PCAC July 23, Q2 earnings August.

No new US adverse events. Medsafe (New Zealand) issued a consumer advisory May 21 2026 warning about "significant health and legal risks" of unapproved peptide products — international regulatory bodies now publicly flagging peptide safety, adding to the journalistic basis for US investigative coverage. PCAC–503B concentration week (July 23 PCAC + July 30 503B comment close) creates a dual-hook amplification structure: two federal compounding-safety events in 7 days is the kind of calendar editors assign investigative features around. 270 days to resolution. Holding.

Katalys: 1 conversion, $300 payout (Trim Rx) — 5-week zero-streak broken. GSC: impressions 1,832 (−42% WoW), clicks 33 (−46%), avg position 22.0. Embody-concentrated traffic. No peptide DTC affiliate programs exist. Pipeline deepening continues to entrench branded GLP-1 CPA dominance: retatrutide NDA Q4 2026 (28.3% weight loss, best-in-class), CagriSema under FDA review (decision expected 2026). Three independent branded GLP-1 programs at $260–500 CPA vs peptide $8–40. MFN deal locks branded pricing architecture. Math structurally unchanged.